Medical Weight Loss

The first visit typically includes a review of medical history, current medications, and weight-loss goals, along with basic health metrics such as weight, blood pressure, and BMI. Bloodwork or lab screening is often ordered to check for underlying conditions that could affect medication choice or safety. Based on those results, the provider determines candidacy and, if appropriate, builds an individualized treatment plan. No medication is prescribed until this medical evaluation is complete.

Semaglutide targets a single hormone receptor (GLP-1), while tirzepatide acts on two receptors (GLP-1 and GIP), which is why the two medications can produce different results and side-effect profiles in different patients. Neither is universally "better" — the choice depends on a patient's health history, prior response to treatment, tolerance for gastrointestinal side effects, and the provider's clinical judgment. Only a prescribing provider can determine which medication is appropriate after reviewing labs and medical history.

Compounded versions of semaglutide and tirzepatide are prepared by licensed compounding pharmacies and are not FDA-approved as standalone products, while brand-name formulations go through full FDA approval. Which formulation a clinic uses can affect cost, availability, and regulatory oversight, so it's worth asking about before starting treatment. A provider can confirm which type is used in a specific treatment plan and explain the reasoning behind that choice.

Patients who aren't candidates for GLP-1 medication due to medical history, lab results, or other health factors can still be evaluated for alternative approaches, since medical weight loss isn't limited to a single medication class. Options may include different prescription therapies, nutrition and lifestyle coaching, or non-invasive body contouring in support of the same goals. A provider determines what's appropriate only after reviewing full medical history and relevant lab work.

Medical weight loss and body contouring are often used together, since medication addresses overall weight while contouring targets areas that don't always respond to weight loss alone, such as loose skin or localized fat. Timing matters, though — providers typically wait until weight has stabilized before recommending body contouring, since further weight change can affect results. Whether combining treatments makes sense depends on individual goals, weight-loss stage, and overall health, and should be discussed directly with a provider.

Requirements vary by clinic and by state regulations governing prescription medication, so patients should confirm the specific format directly with their provider. Many medical weight-loss programs require at least an initial in-person or video evaluation before prescribing, with certain follow-ups handled by phone or telehealth once treatment is underway. Lab work and physical check-ins are typically still required periodically, even in programs offering remote monitoring.

The most commonly reported side effects are gastrointestinal — nausea, constipation, diarrhea, and mild stomach discomfort — and tend to be most noticeable when treatment starts or when a dose changes. These effects are usually temporary and often improve as the body adjusts, though some patients experience them throughout treatment. Less common but more serious risks exist, which is why ongoing medical supervision is part of any properly run program. Patients should report side effects to their provider rather than adjusting or stopping medication on their own.

Weight regain is common after stopping GLP-1 medication if the lifestyle habits built during treatment aren't maintained, since the medication affects appetite and metabolism only while active in the body. Patients who keep the nutrition and activity changes developed during treatment tend to retain more of their results than those who don't. Stopping abruptly isn't generally recommended — a provider can help plan a transition, whether that means tapering, a maintenance approach, or another strategy.

Severe abdominal pain (especially pain radiating to the back), persistent vomiting, or signs of a severe allergic reaction such as facial swelling or difficulty breathing warrant immediate medical care rather than waiting for a scheduled follow-up. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should disclose this before starting treatment, as it may make GLP-1 medication inappropriate. Pregnant patients or those trying to conceive should also inform their provider immediately, since these medications aren't recommended during pregnancy.